BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Treatment
86 results:

  • 1. vhl suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
    Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
    EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A case report of cerebellar hemangioblastoma simulated brain metastasis shown by magnetic resonance imaging.
    Xue J; Mo C
    Medicine (Baltimore); 2024 Feb; 103(6):e37162. PubMed ID: 38335432
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Promising targetable biomarkers in pancreatic neuroendocrine tumours.
    Borghesani M; Gervaso L; Cella CA; Benini L; Ciardiello D; Algeri L; Ferrero A; Valenza C; Guidi L; Zampino MG; Spada F; Fazio N
    Expert Rev Endocrinol Metab; 2023; 18(5):387-398. PubMed ID: 37743651
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
    Marathe DD; Jauslin PM; Kleijn HJ; de Miranda Silva C; Chain A; Bateman T; Shaw PM; Abraham AK; Kauh EA; Liu Y; Perini RF; de Alwis DP; Jain L
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1499-1510. PubMed ID: 37596839
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Selective HIF2A Inhibitors in the Management of Clear Cell Renal cancer and Von Hippel-Lindau-Disease-Associated Tumors.
    Suárez C; Vieito M; Valdivia A; González M; Carles J
    Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Hemangioblastomas and Other Vascular Origating Tumors of Brain or Spinal Cord.
    Vetrano IG; Gioppo A; Faragò G; Pinzi V; Pollo B; Broggi M; Schiariti M; Ferroli P; Acerbi F
    Adv Exp Med Biol; 2023; 1405():377-403. PubMed ID: 37452946
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
    Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
    Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
    Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
    Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The road to systemic therapy in von Hippel-Lindau (vhl) disease: Are we there yet?
    Shepherd STC; Drake WM; Turajlic S
    Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
    Choi WW; Boland JL; Kalola A; Lin J
    Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Belzutifan in a Patient With vhl-Associated Metastatic pancreatic Neuroendocrine Tumor.
    Pelle E; Al-Toubah T; Morse B; Strosberg J
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
    Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
    Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
    Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
    J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
    Louise M Binderup M; Smerdel M; Borgwadt L; Beck Nielsen SS; Madsen MG; Møller HU; Kiilgaard JF; Friis-Hansen L; Harbud V; Cortnum S; Owen H; Gimsing S; Friis Juhl HA; Munthe S; Geilswijk M; Rasmussen ÅK; Møldrup U; Graumann O; Donskov F; Grønbæk H; Stausbøl-Grøn B; Schaffalitzky de Muckadell O; Knigge U; Dam G; Wadt KA; Bøgeskov L; Bagi P; Lund L; Stochholm K; Ousager LB; Sunde L
    Eur J Med Genet; 2022 Aug; 65(8):104538. PubMed ID: 35709961
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Multidisciplinary integrated care pathway for von Hippel-Lindau disease.
    Wolters WPG; Dreijerink KMA; Giles RH; van der Horst-Schrivers ANA; van Nesselrooij B; Zandee WT; Timmers HJLM; Seute T; de Herder WW; Verrijn Stuart AA; Kilic E; Brinkman WM; Zondervan PJ; Vandertop WP; Daniels AB; Wolbers T; Links TP; van Leeuwaarde RS
    Cancer; 2022 Aug; 128(15):2871-2879. PubMed ID: 35579632
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
    N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Belzutifan: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.
    Ito T; Masui T; Komoto I; Doi R; Osamura RY; Sakurai A; Ikeda M; Takano K; Igarashi H; Shimatsu A; Nakamura K; Nakamoto Y; Hijioka S; Morita K; Ishikawa Y; Ohike N; Kasajima A; Kushima R; Kojima M; Sasano H; Hirano S; Mizuno N; Aoki T; Aoki T; Ohtsuka T; Okumura T; Kimura Y; Kudo A; Konishi T; Matsumoto I; Kobayashi N; Fujimori N; Honma Y; Morizane C; Uchino S; Horiuchi K; Yamasaki M; Matsubayashi J; Sato Y; Sekiguchi M; Abe S; Okusaka T; Kida M; Kimura W; Tanaka M; Majima Y; Jensen RT; Hirata K; Imamura M; Uemoto S
    J Gastroenterol; 2021 Nov; 56(11):1033-1044. PubMed ID: 34586495
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
    Terry S; Dalban C; Rioux-Leclercq N; Adam J; Meylan M; Buart S; Bougoüin A; Lespagnol A; Dugay F; Moreno IC; Lacroix G; Lorens JB; Gausdal G; Fridman WH; Mami-Chouaib F; Chaput N; Beuselinck B; Chabaud S; Barros-Monteiro J; Vano Y; Escudier B; Sautès-Fridman C; Albiges L; Chouaib S
    Clin Cancer Res; 2021 Dec; 27(24):6749-6760. PubMed ID: 34407968
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. How 'eye' helped in von Hippel-Lindau syndrome.
    Tyagi S; Kumar KC; Saluja K
    Eur J Ophthalmol; 2023 Jan; 33(1):NP5-NP9. PubMed ID: 34308676
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.